We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. This change lagged the S&P 500's daily gain of 0.22%. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq added 0.22%.
Coming into today, shares of the drugmaker had lost 8.43% in the past month. In that same time, the Medical sector lost 5.2%, while the S&P 500 lost 10.02%.
Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. This would mark year-over-year growth of 10.29%. Our most recent consensus estimate is calling for quarterly revenue of $14.66 billion, up 5% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.02 per share and revenue of $59.63 billion. These totals would mark changes of +10.39% and +6.11%, respectively, from last year.
Any recent changes to analyst estimates for AbbVie should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.3% lower. AbbVie is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, AbbVie currently has a Forward P/E ratio of 9.87. This valuation marks a discount compared to its industry's average Forward P/E of 12.48.
Investors should also note that ABBV has a PEG ratio of 3.89 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
AbbVie (ABBV - Free Report) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. This change lagged the S&P 500's daily gain of 0.22%. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq added 0.22%.
Coming into today, shares of the drugmaker had lost 8.43% in the past month. In that same time, the Medical sector lost 5.2%, while the S&P 500 lost 10.02%.
Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. This would mark year-over-year growth of 10.29%. Our most recent consensus estimate is calling for quarterly revenue of $14.66 billion, up 5% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.02 per share and revenue of $59.63 billion. These totals would mark changes of +10.39% and +6.11%, respectively, from last year.
Any recent changes to analyst estimates for AbbVie should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.3% lower. AbbVie is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, AbbVie currently has a Forward P/E ratio of 9.87. This valuation marks a discount compared to its industry's average Forward P/E of 12.48.
Investors should also note that ABBV has a PEG ratio of 3.89 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.